| 8.87 -0.04 (-0.45%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.36 | 1-year : | 16.4 |
| Resists | First : | 11.44 | Second : | 14.04 |
| Pivot price | 10.83  |
|||
| Supports | First : | 7.23 | Second : | 6.01 |
| MAs | MA(5) : | 9.36 |
MA(20) : | 11.18 |
| MA(100) : | 10.87 |
MA(250) : | 10.1 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 28.5 |
D(3) : | 28.8 |
| RSI | RSI(14): 37.7 |
|||
| 52-week | High : | 14.93 | Low : | 3.89 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ORIC ] has closed above bottom band by 17.5%. Bollinger Bands are 82.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.04 - 9.09 | 9.09 - 9.13 |
| Low: | 8.57 - 8.62 | 8.62 - 8.66 |
| Close: | 8.78 - 8.87 | 8.87 - 8.95 |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Tue, 07 Apr 2026
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.com
Mon, 06 Apr 2026
JonesTrading Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $25 - Moomoo
Mon, 06 Apr 2026
ORIC Pharma drops after early-stage trial data for prostate cancer therapy - MSN
Mon, 06 Apr 2026
ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to - GlobeNewswire
Sun, 05 Apr 2026
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Advancing Rinzimetostat To A Phase 3 Prostate Cancer Trial - simplywall.st
Fri, 03 Apr 2026
ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history - Yahoo Finance Australia
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 112 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 117.5 (%) |
| Shares Short | 20,650 (K) |
| Shares Short P.Month | 22,100 (K) |
| EPS | -1.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.9 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.2 % |
| Return on Equity (ttm) | -41.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -111 (M) |
| Levered Free Cash Flow | -69 (M) |
| PE Ratio | -6.04 |
| PEG Ratio | 0 |
| Price to Book value | 2.27 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|